Levilimab
is novel monoclonal anti-IL-6 receptor antibody. As tocilizumab and
sarilumab are already approved drugs in rheumatology, and olokizumab
[1] has been presented at the 2020 EULAR Online Meeting in a phase 3
study, I'm suprised seeing another actor on the IL-6 stage. And there
are still others like monoclonal
anti-il-6 receptor antibodies: clazakinumab, elsilimomab,
sirukumab; and more in oncology like siltuximab.
V.
Mazurov and colleagues presented 1-year
results of the phase 2 AURORA study
[2]. AURORA assessed efficacy and safety of two dosing regimens of
levilimab in patients with active rheumatoid arthritis and inadequate
response to methotrexate (primary endpoint). Secondary endpoints
mentioned: ACR20/50/70, LDA, remission rates, and
DAS28-CRP(4); more data collected. Levilimab plus MTX showed
sustained efficacy with continuous clinical improvement. The safety
profile of levilimab was consistent with other IL-6 receptor
inhibitors.
Do
we need more IL-6-Inhibitors? Levilimab, clazakinumab,
elsilimomab, sirukumab as well as the established tocilizumab,
sarilumab, and siltuximab? I guess no, but that's the luxury of a free
market economy.
Links
and References:
[2]
V. Mazurov1, E. Zotkin2, E. Ilivanova3, T. Kropotina4, T. Plaksina5,
O. Nesmeyanova6, N. Soroka7, A. Kundzer8, A. Lutskii9, E. Dokukina9,
A. Eremeeva9, A. Zinkina-Orihan9. FRI0114
EFFICACY OF LEVILIMAB, NOVEL
MONOCLONAL ANTI-IL-6 RECEPTOR ANTIBODY, IN COMBINATION WITH
METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS: 1-YEAR RESULTS OF
PHASE 2 AURORA STUDY. DOI:
10.1136/annrheumdis-2020-eular.5465
.
No comments:
Post a Comment